nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—ABCB1—Mitomycin—urinary bladder cancer	0.227	0.379	CbGbCtD
Methylprednisolone—CYP3A4—Thiotepa—urinary bladder cancer	0.103	0.172	CbGbCtD
Methylprednisolone—ABCB1—Gemcitabine—urinary bladder cancer	0.0654	0.109	CbGbCtD
Methylprednisolone—ABCB1—Cisplatin—urinary bladder cancer	0.0475	0.0792	CbGbCtD
Methylprednisolone—ABCB1—Etoposide—urinary bladder cancer	0.0467	0.0779	CbGbCtD
Methylprednisolone—ABCB1—Doxorubicin—urinary bladder cancer	0.0318	0.0531	CbGbCtD
Methylprednisolone—ABCB1—Methotrexate—urinary bladder cancer	0.0308	0.0514	CbGbCtD
Methylprednisolone—CYP3A4—Etoposide—urinary bladder cancer	0.028	0.0466	CbGbCtD
Methylprednisolone—CYP3A4—Doxorubicin—urinary bladder cancer	0.0191	0.0318	CbGbCtD
Methylprednisolone—NR3C1—urine—urinary bladder cancer	0.00445	0.19	CbGeAlD
Methylprednisolone—CYP3A4—urine—urinary bladder cancer	0.00336	0.144	CbGeAlD
Methylprednisolone—ABCB1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00332	0.0868	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—BPTF—urinary bladder cancer	0.00212	0.0555	CbGpPWpGaD
Methylprednisolone—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00204	0.0535	CbGpPWpGaD
Methylprednisolone—NR3C1—prostate gland—urinary bladder cancer	0.0016	0.0683	CbGeAlD
Methylprednisolone—NR3C1—Signaling events mediated by HDAC Class II—HDAC4—urinary bladder cancer	0.0014	0.0367	CbGpPWpGaD
Methylprednisolone—NR3C1—seminal vesicle—urinary bladder cancer	0.00135	0.0577	CbGeAlD
Methylprednisolone—NR3C1—epithelium—urinary bladder cancer	0.00117	0.0502	CbGeAlD
Methylprednisolone—NR3C1—smooth muscle tissue—urinary bladder cancer	0.00113	0.0483	CbGeAlD
Methylprednisolone—NR3C1—renal system—urinary bladder cancer	0.00109	0.0465	CbGeAlD
Methylprednisolone—NR3C1—urethra—urinary bladder cancer	0.00107	0.0457	CbGeAlD
Methylprednisolone—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00107	0.028	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—KRT5—urinary bladder cancer	0.000959	0.0251	CbGpPWpGaD
Methylprednisolone—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000944	0.0247	CbGpPWpGaD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000938	0.0246	CbGpPWpGaD
Methylprednisolone—NR3C1—female reproductive system—urinary bladder cancer	0.000871	0.0373	CbGeAlD
Methylprednisolone—ABCB1—prostate gland—urinary bladder cancer	0.000855	0.0365	CbGeAlD
Methylprednisolone—CYP3A4—renal system—urinary bladder cancer	0.000823	0.0352	CbGeAlD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MT2A—urinary bladder cancer	0.000809	0.0212	CbGpPWpGaD
Methylprednisolone—NR3C1—vagina—urinary bladder cancer	0.000788	0.0337	CbGeAlD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000766	0.02	CbGpPWpGaD
Methylprednisolone—ABCB1—seminal vesicle—urinary bladder cancer	0.000723	0.0309	CbGeAlD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.000687	0.018	CbGpPWpGaD
Methylprednisolone—NR3C1—Nuclear Receptors—ESR2—urinary bladder cancer	0.00068	0.0178	CbGpPWpGaD
Methylprednisolone—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000673	0.0176	CbGpPWpGaD
Methylprednisolone—CYP3A4—female reproductive system—urinary bladder cancer	0.000659	0.0282	CbGeAlD
Methylprednisolone—ABCB1—epithelium—urinary bladder cancer	0.000628	0.0269	CbGeAlD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—PPARG—urinary bladder cancer	0.000583	0.0153	CbGpPWpGaD
Methylprednisolone—ABCB1—renal system—urinary bladder cancer	0.000582	0.0249	CbGeAlD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000578	0.0151	CbGpPWpGaD
Methylprednisolone—ABCB1—urethra—urinary bladder cancer	0.000572	0.0245	CbGeAlD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.000538	0.0141	CbGpPWpGaD
Methylprednisolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—urinary bladder cancer	0.000537	0.014	CbGpPWpGaD
Methylprednisolone—NR3C1—lymph node—urinary bladder cancer	0.00051	0.0218	CbGeAlD
Methylprednisolone—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000481	0.0126	CbGpPWpGaD
Methylprednisolone—ABCB1—female reproductive system—urinary bladder cancer	0.000466	0.0199	CbGeAlD
Methylprednisolone—ABCB1—vagina—urinary bladder cancer	0.000422	0.018	CbGeAlD
Methylprednisolone—NR3C1—Nuclear Receptors—ESR1—urinary bladder cancer	0.000413	0.0108	CbGpPWpGaD
Methylprednisolone—NR3C1—Signaling events mediated by HDAC Class II—ESR1—urinary bladder cancer	0.000413	0.0108	CbGpPWpGaD
Methylprednisolone—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000412	0.0108	CbGpPWpGaD
Methylprednisolone—NR3C1—Circadian Clock—NCOR1—urinary bladder cancer	0.000391	0.0102	CbGpPWpGaD
Methylprednisolone—NR3C1—Nuclear Receptors—PPARG—urinary bladder cancer	0.000376	0.00985	CbGpPWpGaD
Methylprednisolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—urinary bladder cancer	0.000369	0.00967	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000367	0.00961	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000362	0.00948	CbGpPWpGaD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.000326	0.00853	CbGpPWpGaD
Methylprednisolone—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000316	0.00827	CbGpPWpGaD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—TNF—urinary bladder cancer	0.000309	0.0081	CbGpPWpGaD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000306	0.000904	CcSEcCtD
Methylprednisolone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000306	0.000902	CcSEcCtD
Methylprednisolone—Pancreatitis—Methotrexate—urinary bladder cancer	0.000305	0.000901	CcSEcCtD
Methylprednisolone—Discomfort—Etoposide—urinary bladder cancer	0.000305	0.000899	CcSEcCtD
Methylprednisolone—Breast disorder—Epirubicin—urinary bladder cancer	0.000305	0.000899	CcSEcCtD
Methylprednisolone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000303	0.000895	CcSEcCtD
Methylprednisolone—Hypotension—Cisplatin—urinary bladder cancer	0.000302	0.00089	CcSEcCtD
Methylprednisolone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.0003	0.000885	CcSEcCtD
Methylprednisolone—Fatigue—Gemcitabine—urinary bladder cancer	0.000299	0.000881	CcSEcCtD
Methylprednisolone—Confusional state—Etoposide—urinary bladder cancer	0.000298	0.00088	CcSEcCtD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000298	0.00779	CbGpPWpGaD
Methylprednisolone—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000297	0.000878	CcSEcCtD
Methylprednisolone—Muscular weakness—Epirubicin—urinary bladder cancer	0.000297	0.000878	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.000297	0.00778	CbGpPWpGaD
Methylprednisolone—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000297	0.000876	CcSEcCtD
Methylprednisolone—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000296	0.00776	CbGpPWpGaD
Methylprednisolone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000296	0.000873	CcSEcCtD
Methylprednisolone—Mood swings—Doxorubicin—urinary bladder cancer	0.000296	0.000872	CcSEcCtD
Methylprednisolone—Asthenia—Thiotepa—urinary bladder cancer	0.000295	0.000872	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000294	0.000868	CcSEcCtD
Methylprednisolone—Infection—Etoposide—urinary bladder cancer	0.000294	0.000867	CcSEcCtD
Methylprednisolone—Abdominal distension—Epirubicin—urinary bladder cancer	0.000293	0.000866	CcSEcCtD
Methylprednisolone—Pruritus—Thiotepa—urinary bladder cancer	0.000291	0.00086	CcSEcCtD
Methylprednisolone—Paraesthesia—Cisplatin—urinary bladder cancer	0.00029	0.000855	CcSEcCtD
Methylprednisolone—Tachycardia—Etoposide—urinary bladder cancer	0.000289	0.000852	CcSEcCtD
Methylprednisolone—Skin disorder—Etoposide—urinary bladder cancer	0.000287	0.000848	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.000287	0.0075	CbGpPWpGaD
Methylprednisolone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000286	0.000844	CcSEcCtD
Methylprednisolone—Pancreatitis—Epirubicin—urinary bladder cancer	0.000286	0.000843	CcSEcCtD
Methylprednisolone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000285	0.000842	CcSEcCtD
Methylprednisolone—Breast disorder—Doxorubicin—urinary bladder cancer	0.000282	0.000832	CcSEcCtD
Methylprednisolone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000282	0.000831	CcSEcCtD
Methylprednisolone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000281	0.000828	CcSEcCtD
Methylprednisolone—Infestation—Methotrexate—urinary bladder cancer	0.000278	0.00082	CcSEcCtD
Methylprednisolone—Infestation NOS—Methotrexate—urinary bladder cancer	0.000278	0.00082	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.000277	0.00725	CbGpPWpGaD
Methylprednisolone—Hypotension—Etoposide—urinary bladder cancer	0.000276	0.000815	CcSEcCtD
Methylprednisolone—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000275	0.000812	CcSEcCtD
Methylprednisolone—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000275	0.000812	CcSEcCtD
Methylprednisolone—ABCB1—lymph node—urinary bladder cancer	0.000273	0.0117	CbGeAlD
Methylprednisolone—Dizziness—Thiotepa—urinary bladder cancer	0.000272	0.000803	CcSEcCtD
Methylprednisolone—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000272	0.000801	CcSEcCtD
Methylprednisolone—Urticaria—Fluorouracil—urinary bladder cancer	0.000271	0.000798	CcSEcCtD
Methylprednisolone—NR3C1—Circadian Clock—CREBBP—urinary bladder cancer	0.000269	0.00704	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—PLAU—urinary bladder cancer	0.000269	0.00704	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000267	0.00698	CbGpPWpGaD
Methylprednisolone—Sweating—Methotrexate—urinary bladder cancer	0.000266	0.000786	CcSEcCtD
Methylprednisolone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000266	0.000785	CcSEcCtD
Methylprednisolone—Paraesthesia—Etoposide—urinary bladder cancer	0.000266	0.000784	CcSEcCtD
Methylprednisolone—Weight increased—Epirubicin—urinary bladder cancer	0.000265	0.000783	CcSEcCtD
Methylprednisolone—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000264	0.00078	CcSEcCtD
Methylprednisolone—Vomiting—Thiotepa—urinary bladder cancer	0.000262	0.000772	CcSEcCtD
Methylprednisolone—Infestation NOS—Epirubicin—urinary bladder cancer	0.00026	0.000767	CcSEcCtD
Methylprednisolone—Infestation—Epirubicin—urinary bladder cancer	0.00026	0.000767	CcSEcCtD
Methylprednisolone—Rash—Thiotepa—urinary bladder cancer	0.00026	0.000766	CcSEcCtD
Methylprednisolone—Dermatitis—Thiotepa—urinary bladder cancer	0.000259	0.000765	CcSEcCtD
Methylprednisolone—Headache—Thiotepa—urinary bladder cancer	0.000258	0.000761	CcSEcCtD
Methylprednisolone—Fatigue—Etoposide—urinary bladder cancer	0.000255	0.000752	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000255	0.000752	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.000253	0.00662	CbGpPWpGaD
Methylprednisolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—urinary bladder cancer	0.000252	0.00658	CbGpPWpGaD
Methylprednisolone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000251	0.00074	CcSEcCtD
Methylprednisolone—Haemoglobin—Methotrexate—urinary bladder cancer	0.000251	0.00074	CcSEcCtD
Methylprednisolone—Haemorrhage—Methotrexate—urinary bladder cancer	0.000249	0.000736	CcSEcCtD
Methylprednisolone—Sweating—Epirubicin—urinary bladder cancer	0.000249	0.000735	CcSEcCtD
Methylprednisolone—Asthenia—Gemcitabine—urinary bladder cancer	0.000248	0.000733	CcSEcCtD
Methylprednisolone—Weight increased—Doxorubicin—urinary bladder cancer	0.000245	0.000724	CcSEcCtD
Methylprednisolone—Pruritus—Gemcitabine—urinary bladder cancer	0.000245	0.000723	CcSEcCtD
Methylprednisolone—Nausea—Thiotepa—urinary bladder cancer	0.000245	0.000722	CcSEcCtD
Methylprednisolone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000244	0.000719	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000242	0.000714	CcSEcCtD
Methylprednisolone—Pruritus—Fluorouracil—urinary bladder cancer	0.000241	0.000711	CcSEcCtD
Methylprednisolone—Infestation—Doxorubicin—urinary bladder cancer	0.00024	0.00071	CcSEcCtD
Methylprednisolone—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00024	0.00071	CcSEcCtD
Methylprednisolone—Visual impairment—Methotrexate—urinary bladder cancer	0.00024	0.000709	CcSEcCtD
Methylprednisolone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000238	0.000702	CcSEcCtD
Methylprednisolone—Bradycardia—Epirubicin—urinary bladder cancer	0.000238	0.000701	CcSEcCtD
Methylprednisolone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000237	0.000699	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000236	0.000696	CcSEcCtD
Methylprednisolone—Urticaria—Etoposide—urinary bladder cancer	0.000235	0.000693	CcSEcCtD
Methylprednisolone—Haemoglobin—Epirubicin—urinary bladder cancer	0.000235	0.000692	CcSEcCtD
Methylprednisolone—Rhinitis—Epirubicin—urinary bladder cancer	0.000234	0.00069	CcSEcCtD
Methylprednisolone—Abdominal pain—Etoposide—urinary bladder cancer	0.000234	0.00069	CcSEcCtD
Methylprednisolone—Haemorrhage—Epirubicin—urinary bladder cancer	0.000233	0.000689	CcSEcCtD
Methylprednisolone—Eye disorder—Methotrexate—urinary bladder cancer	0.000233	0.000688	CcSEcCtD
Methylprednisolone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000233	0.000688	CcSEcCtD
Methylprednisolone—Asthenia—Cisplatin—urinary bladder cancer	0.000232	0.000683	CcSEcCtD
Methylprednisolone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000231	0.000683	CcSEcCtD
Methylprednisolone—Sweating—Doxorubicin—urinary bladder cancer	0.000231	0.00068	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000229	0.000677	CcSEcCtD
Methylprednisolone—Angiopathy—Methotrexate—urinary bladder cancer	0.000226	0.000668	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.000226	0.00592	CbGpPWpGaD
Methylprednisolone—Immune system disorder—Methotrexate—urinary bladder cancer	0.000225	0.000665	CcSEcCtD
Methylprednisolone—Dizziness—Fluorouracil—urinary bladder cancer	0.000225	0.000665	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.000225	0.00589	CbGpPWpGaD
Methylprednisolone—Visual impairment—Epirubicin—urinary bladder cancer	0.000225	0.000664	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000225	0.000663	CcSEcCtD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000221	0.00578	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000221	0.000652	CcSEcCtD
Methylprednisolone—Vomiting—Gemcitabine—urinary bladder cancer	0.00022	0.00065	CcSEcCtD
Methylprednisolone—Bradycardia—Doxorubicin—urinary bladder cancer	0.00022	0.000649	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00022	0.00575	CbGpPWpGaD
Methylprednisolone—Mental disorder—Methotrexate—urinary bladder cancer	0.000218	0.000645	CcSEcCtD
Methylprednisolone—Rash—Gemcitabine—urinary bladder cancer	0.000218	0.000644	CcSEcCtD
Methylprednisolone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000218	0.000644	CcSEcCtD
Methylprednisolone—Eye disorder—Epirubicin—urinary bladder cancer	0.000218	0.000643	CcSEcCtD
Methylprednisolone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000218	0.000643	CcSEcCtD
Methylprednisolone—Malnutrition—Methotrexate—urinary bladder cancer	0.000217	0.000641	CcSEcCtD
Methylprednisolone—Erythema—Methotrexate—urinary bladder cancer	0.000217	0.000641	CcSEcCtD
Methylprednisolone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000217	0.00064	CcSEcCtD
Methylprednisolone—Headache—Gemcitabine—urinary bladder cancer	0.000217	0.00064	CcSEcCtD
Methylprednisolone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000217	0.000639	CcSEcCtD
Methylprednisolone—Vomiting—Fluorouracil—urinary bladder cancer	0.000217	0.000639	CcSEcCtD
Methylprednisolone—Rhinitis—Doxorubicin—urinary bladder cancer	0.000216	0.000639	CcSEcCtD
Methylprednisolone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000216	0.000637	CcSEcCtD
Methylprednisolone—Rash—Fluorouracil—urinary bladder cancer	0.000215	0.000634	CcSEcCtD
Methylprednisolone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000214	0.000633	CcSEcCtD
Methylprednisolone—Headache—Fluorouracil—urinary bladder cancer	0.000213	0.00063	CcSEcCtD
Methylprednisolone—Asthenia—Etoposide—urinary bladder cancer	0.000212	0.000626	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000212	0.000626	CcSEcCtD
Methylprednisolone—Angiopathy—Epirubicin—urinary bladder cancer	0.000212	0.000625	CcSEcCtD
Methylprednisolone—Immune system disorder—Epirubicin—urinary bladder cancer	0.000211	0.000622	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00021	0.000621	CcSEcCtD
Methylprednisolone—Pruritus—Etoposide—urinary bladder cancer	0.000209	0.000617	CcSEcCtD
Methylprednisolone—Arrhythmia—Epirubicin—urinary bladder cancer	0.000208	0.000615	CcSEcCtD
Methylprednisolone—Visual impairment—Doxorubicin—urinary bladder cancer	0.000208	0.000614	CcSEcCtD
Methylprednisolone—Nausea—Gemcitabine—urinary bladder cancer	0.000206	0.000607	CcSEcCtD
Methylprednisolone—Vomiting—Cisplatin—urinary bladder cancer	0.000205	0.000606	CcSEcCtD
Methylprednisolone—Mental disorder—Epirubicin—urinary bladder cancer	0.000204	0.000603	CcSEcCtD
Methylprednisolone—Rash—Cisplatin—urinary bladder cancer	0.000204	0.000601	CcSEcCtD
Methylprednisolone—Dermatitis—Cisplatin—urinary bladder cancer	0.000203	0.0006	CcSEcCtD
Methylprednisolone—Erythema—Epirubicin—urinary bladder cancer	0.000203	0.000599	CcSEcCtD
Methylprednisolone—Malnutrition—Epirubicin—urinary bladder cancer	0.000203	0.000599	CcSEcCtD
Methylprednisolone—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000202	0.0053	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Etoposide—urinary bladder cancer	0.000202	0.000597	CcSEcCtD
Methylprednisolone—Nausea—Fluorouracil—urinary bladder cancer	0.000202	0.000597	CcSEcCtD
Methylprednisolone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000202	0.000595	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000201	0.000594	CcSEcCtD
Methylprednisolone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.0002	0.000591	CcSEcCtD
Methylprednisolone—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.0002	0.00523	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000197	0.00516	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.000196	0.00514	CbGpPWpGaD
Methylprednisolone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000196	0.000578	CcSEcCtD
Methylprednisolone—Malaise—Methotrexate—urinary bladder cancer	0.000196	0.000578	CcSEcCtD
Methylprednisolone—Dizziness—Etoposide—urinary bladder cancer	0.000196	0.000577	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.000195	0.00511	CbGpPWpGaD
Methylprednisolone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000195	0.000575	CcSEcCtD
Methylprednisolone—Vertigo—Methotrexate—urinary bladder cancer	0.000195	0.000575	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000195	0.000574	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000194	0.00508	CbGpPWpGaD
Methylprednisolone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000193	0.000569	CcSEcCtD
Methylprednisolone—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000192	0.00502	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000192	0.00502	CbGpPWpGaD
Methylprednisolone—Nausea—Cisplatin—urinary bladder cancer	0.000192	0.000566	CcSEcCtD
Methylprednisolone—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000189	0.00495	CbGpPWpGaD
Methylprednisolone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000189	0.000558	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000189	0.00494	CbGpPWpGaD
Methylprednisolone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000188	0.000556	CcSEcCtD
Methylprednisolone—Convulsion—Methotrexate—urinary bladder cancer	0.000188	0.000555	CcSEcCtD
Methylprednisolone—Vomiting—Etoposide—urinary bladder cancer	0.000188	0.000555	CcSEcCtD
Methylprednisolone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000188	0.000555	CcSEcCtD
Methylprednisolone—Erythema—Doxorubicin—urinary bladder cancer	0.000188	0.000555	CcSEcCtD
Methylprednisolone—Rash—Etoposide—urinary bladder cancer	0.000186	0.00055	CcSEcCtD
Methylprednisolone—Dermatitis—Etoposide—urinary bladder cancer	0.000186	0.00055	CcSEcCtD
Methylprednisolone—Headache—Etoposide—urinary bladder cancer	0.000185	0.000547	CcSEcCtD
Methylprednisolone—Arthralgia—Methotrexate—urinary bladder cancer	0.000185	0.000545	CcSEcCtD
Methylprednisolone—Myalgia—Methotrexate—urinary bladder cancer	0.000185	0.000545	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000184	0.000542	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000183	0.0048	CbGpPWpGaD
Methylprednisolone—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.000183	0.00479	CbGpPWpGaD
Methylprednisolone—Malaise—Epirubicin—urinary bladder cancer	0.000183	0.000541	CcSEcCtD
Methylprednisolone—Discomfort—Methotrexate—urinary bladder cancer	0.000183	0.000539	CcSEcCtD
Methylprednisolone—Vertigo—Epirubicin—urinary bladder cancer	0.000182	0.000539	CcSEcCtD
Methylprednisolone—Syncope—Epirubicin—urinary bladder cancer	0.000182	0.000538	CcSEcCtD
Methylprednisolone—Confusional state—Methotrexate—urinary bladder cancer	0.000179	0.000527	CcSEcCtD
Methylprednisolone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000179	0.000527	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000177	0.000523	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000176	0.00461	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.000176	0.00461	CbGpPWpGaD
Methylprednisolone—Convulsion—Epirubicin—urinary bladder cancer	0.000176	0.000519	CcSEcCtD
Methylprednisolone—Infection—Methotrexate—urinary bladder cancer	0.000176	0.000519	CcSEcCtD
Methylprednisolone—Nausea—Etoposide—urinary bladder cancer	0.000176	0.000518	CcSEcCtD
Methylprednisolone—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000176	0.00459	CbGpPWpGaD
Methylprednisolone—Hypertension—Epirubicin—urinary bladder cancer	0.000175	0.000518	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000174	0.000515	CcSEcCtD
Methylprednisolone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000174	0.000513	CcSEcCtD
Methylprednisolone—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000173	0.00453	CbGpPWpGaD
Methylprednisolone—Myalgia—Epirubicin—urinary bladder cancer	0.000173	0.00051	CcSEcCtD
Methylprednisolone—Arthralgia—Epirubicin—urinary bladder cancer	0.000173	0.00051	CcSEcCtD
Methylprednisolone—Anxiety—Epirubicin—urinary bladder cancer	0.000172	0.000509	CcSEcCtD
Methylprednisolone—Skin disorder—Methotrexate—urinary bladder cancer	0.000172	0.000508	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000172	0.000507	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000171	0.000505	CcSEcCtD
Methylprednisolone—Discomfort—Epirubicin—urinary bladder cancer	0.000171	0.000504	CcSEcCtD
Methylprednisolone—Malaise—Doxorubicin—urinary bladder cancer	0.000169	0.0005	CcSEcCtD
Methylprednisolone—Vertigo—Doxorubicin—urinary bladder cancer	0.000169	0.000498	CcSEcCtD
Methylprednisolone—Syncope—Doxorubicin—urinary bladder cancer	0.000169	0.000497	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000168	0.0044	CbGpPWpGaD
Methylprednisolone—Confusional state—Epirubicin—urinary bladder cancer	0.000167	0.000493	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000166	0.000489	CcSEcCtD
Methylprednisolone—Hypotension—Methotrexate—urinary bladder cancer	0.000166	0.000488	CcSEcCtD
Methylprednisolone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000165	0.000487	CcSEcCtD
Methylprednisolone—Infection—Epirubicin—urinary bladder cancer	0.000165	0.000486	CcSEcCtD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000165	0.00431	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000164	0.00429	CbGpPWpGaD
Methylprednisolone—Shock—Epirubicin—urinary bladder cancer	0.000163	0.000481	CcSEcCtD
Methylprednisolone—Convulsion—Doxorubicin—urinary bladder cancer	0.000163	0.000481	CcSEcCtD
Methylprednisolone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000163	0.00048	CcSEcCtD
Methylprednisolone—Hypertension—Doxorubicin—urinary bladder cancer	0.000162	0.000479	CcSEcCtD
Methylprednisolone—Tachycardia—Epirubicin—urinary bladder cancer	0.000162	0.000477	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000161	0.000476	CcSEcCtD
Methylprednisolone—Skin disorder—Epirubicin—urinary bladder cancer	0.000161	0.000475	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00016	0.000473	CcSEcCtD
Methylprednisolone—Insomnia—Methotrexate—urinary bladder cancer	0.00016	0.000473	CcSEcCtD
Methylprednisolone—Arthralgia—Doxorubicin—urinary bladder cancer	0.00016	0.000472	CcSEcCtD
Methylprednisolone—Myalgia—Doxorubicin—urinary bladder cancer	0.00016	0.000472	CcSEcCtD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.00016	0.00418	CbGpPWpGaD
Methylprednisolone—Anxiety—Doxorubicin—urinary bladder cancer	0.000159	0.000471	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.000159	0.00417	CbGpPWpGaD
Methylprednisolone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000159	0.000469	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000159	0.000469	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.000158	0.00414	CbGpPWpGaD
Methylprednisolone—Discomfort—Doxorubicin—urinary bladder cancer	0.000158	0.000467	CcSEcCtD
Methylprednisolone—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000158	0.00414	CbGpPWpGaD
Methylprednisolone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000156	0.00046	CcSEcCtD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000156	0.00408	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.000155	0.00406	CbGpPWpGaD
Methylprednisolone—Hypotension—Epirubicin—urinary bladder cancer	0.000155	0.000457	CcSEcCtD
Methylprednisolone—Confusional state—Doxorubicin—urinary bladder cancer	0.000155	0.000456	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000153	0.000453	CcSEcCtD
Methylprednisolone—Fatigue—Methotrexate—urinary bladder cancer	0.000153	0.000451	CcSEcCtD
Methylprednisolone—Infection—Doxorubicin—urinary bladder cancer	0.000152	0.00045	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	0.000151	0.00395	CbGpPWpGaD
Methylprednisolone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000151	0.000446	CcSEcCtD
Methylprednisolone—Shock—Doxorubicin—urinary bladder cancer	0.000151	0.000445	CcSEcCtD
Methylprednisolone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00015	0.000444	CcSEcCtD
Methylprednisolone—Insomnia—Epirubicin—urinary bladder cancer	0.00015	0.000442	CcSEcCtD
Methylprednisolone—Tachycardia—Doxorubicin—urinary bladder cancer	0.00015	0.000442	CcSEcCtD
Methylprednisolone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000149	0.00044	CcSEcCtD
Methylprednisolone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000149	0.000439	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	0.000148	0.00388	CbGpPWpGaD
Methylprednisolone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000148	0.000438	CcSEcCtD
Methylprednisolone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000146	0.000431	CcSEcCtD
Methylprednisolone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000146	0.000431	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000145	0.000427	CcSEcCtD
Methylprednisolone—Hypotension—Doxorubicin—urinary bladder cancer	0.000143	0.000423	CcSEcCtD
Methylprednisolone—Fatigue—Epirubicin—urinary bladder cancer	0.000143	0.000422	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.000141	0.0037	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000141	0.00369	CbGpPWpGaD
Methylprednisolone—Urticaria—Methotrexate—urinary bladder cancer	0.000141	0.000415	CcSEcCtD
Methylprednisolone—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	0.000141	0.00368	CbGpPWpGaD
Methylprednisolone—Abdominal pain—Methotrexate—urinary bladder cancer	0.00014	0.000413	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	0.00014	0.00366	CbGpPWpGaD
Methylprednisolone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00014	0.000412	CcSEcCtD
Methylprednisolone—Insomnia—Doxorubicin—urinary bladder cancer	0.000139	0.000409	CcSEcCtD
Methylprednisolone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000138	0.000406	CcSEcCtD
Methylprednisolone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000137	0.000403	CcSEcCtD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000136	0.00356	CbGpPWpGaD
Methylprednisolone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000136	0.0004	CcSEcCtD
Methylprednisolone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000135	0.000398	CcSEcCtD
Methylprednisolone—NR3C1—Adipogenesis—RB1—urinary bladder cancer	0.000135	0.00352	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.000134	0.00352	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	0.000133	0.00349	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	0.000133	0.00348	CbGpPWpGaD
Methylprednisolone—Fatigue—Doxorubicin—urinary bladder cancer	0.000132	0.00039	CcSEcCtD
Methylprednisolone—Urticaria—Epirubicin—urinary bladder cancer	0.000132	0.000389	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.000132	0.00344	CbGpPWpGaD
Methylprednisolone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000131	0.000387	CcSEcCtD
Methylprednisolone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000131	0.000385	CcSEcCtD
Methylprednisolone—Asthenia—Methotrexate—urinary bladder cancer	0.000127	0.000375	CcSEcCtD
Methylprednisolone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000126	0.000373	CcSEcCtD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000125	0.00328	CbGpPWpGaD
Methylprednisolone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000125	0.00037	CcSEcCtD
Methylprednisolone—Pruritus—Methotrexate—urinary bladder cancer	0.000125	0.00037	CcSEcCtD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000125	0.00327	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000125	0.00326	CbGpPWpGaD
Methylprednisolone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000122	0.00036	CcSEcCtD
Methylprednisolone—Urticaria—Doxorubicin—urinary bladder cancer	0.000122	0.00036	CcSEcCtD
Methylprednisolone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000121	0.000358	CcSEcCtD
Methylprednisolone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000121	0.000358	CcSEcCtD
Methylprednisolone—Asthenia—Epirubicin—urinary bladder cancer	0.000119	0.000351	CcSEcCtD
Methylprednisolone—Pruritus—Epirubicin—urinary bladder cancer	0.000117	0.000346	CcSEcCtD
Methylprednisolone—Dizziness—Methotrexate—urinary bladder cancer	0.000117	0.000346	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000117	0.00306	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000117	0.00306	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000114	0.00298	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000113	0.000335	CcSEcCtD
Methylprednisolone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000113	0.000333	CcSEcCtD
Methylprednisolone—Vomiting—Methotrexate—urinary bladder cancer	0.000113	0.000332	CcSEcCtD
Methylprednisolone—Rash—Methotrexate—urinary bladder cancer	0.000112	0.00033	CcSEcCtD
Methylprednisolone—Dermatitis—Methotrexate—urinary bladder cancer	0.000112	0.000329	CcSEcCtD
Methylprednisolone—Headache—Methotrexate—urinary bladder cancer	0.000111	0.000327	CcSEcCtD
Methylprednisolone—Asthenia—Doxorubicin—urinary bladder cancer	0.00011	0.000325	CcSEcCtD
Methylprednisolone—Dizziness—Epirubicin—urinary bladder cancer	0.00011	0.000323	CcSEcCtD
Methylprednisolone—Pruritus—Doxorubicin—urinary bladder cancer	0.000109	0.00032	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	0.000108	0.00283	CbGpPWpGaD
Methylprednisolone—Vomiting—Epirubicin—urinary bladder cancer	0.000105	0.000311	CcSEcCtD
Methylprednisolone—Nausea—Methotrexate—urinary bladder cancer	0.000105	0.000311	CcSEcCtD
Methylprednisolone—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000105	0.00275	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000105	0.00031	CcSEcCtD
Methylprednisolone—Rash—Epirubicin—urinary bladder cancer	0.000105	0.000308	CcSEcCtD
Methylprednisolone—Dermatitis—Epirubicin—urinary bladder cancer	0.000104	0.000308	CcSEcCtD
Methylprednisolone—Headache—Epirubicin—urinary bladder cancer	0.000104	0.000306	CcSEcCtD
Methylprednisolone—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000104	0.00271	CbGpPWpGaD
Methylprednisolone—Dizziness—Doxorubicin—urinary bladder cancer	0.000101	0.000299	CcSEcCtD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.0001	0.00263	CbGpPWpGaD
Methylprednisolone—Nausea—Epirubicin—urinary bladder cancer	9.85e-05	0.000291	CcSEcCtD
Methylprednisolone—Vomiting—Doxorubicin—urinary bladder cancer	9.75e-05	0.000288	CcSEcCtD
Methylprednisolone—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	9.67e-05	0.00253	CbGpPWpGaD
Methylprednisolone—Rash—Doxorubicin—urinary bladder cancer	9.67e-05	0.000285	CcSEcCtD
Methylprednisolone—Dermatitis—Doxorubicin—urinary bladder cancer	9.66e-05	0.000285	CcSEcCtD
Methylprednisolone—Headache—Doxorubicin—urinary bladder cancer	9.61e-05	0.000284	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	9.52e-05	0.00249	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	9.41e-05	0.00246	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	9.28e-05	0.00243	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	9.28e-05	0.00243	CbGpPWpGaD
Methylprednisolone—Nausea—Doxorubicin—urinary bladder cancer	9.11e-05	0.000269	CcSEcCtD
Methylprednisolone—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	8.59e-05	0.00225	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	8.51e-05	0.00223	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	8.41e-05	0.0022	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8.22e-05	0.00215	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	8.21e-05	0.00215	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	8.15e-05	0.00213	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	7.99e-05	0.00209	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	7.96e-05	0.00208	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	7.84e-05	0.00205	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—TNF—urinary bladder cancer	7.47e-05	0.00196	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	7.17e-05	0.00188	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	6.95e-05	0.00182	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.7e-05	0.00175	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	6.46e-05	0.00169	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.14e-05	0.00161	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.12e-05	0.0016	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.09e-05	0.00159	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	5.98e-05	0.00156	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.65e-05	0.00148	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	5.63e-05	0.00147	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	5.62e-05	0.00147	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.57e-05	0.00146	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.34e-05	0.0014	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTO2—urinary bladder cancer	5.33e-05	0.00139	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—NAT1—urinary bladder cancer	5.33e-05	0.00139	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.27e-05	0.00138	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.19e-05	0.00136	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	5.14e-05	0.00134	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	5.13e-05	0.00134	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.12e-05	0.00134	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	4.94e-05	0.00129	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	4.87e-05	0.00128	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.53e-05	0.00119	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—ESR2—urinary bladder cancer	4.47e-05	0.00117	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.47e-05	0.00117	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	4.39e-05	0.00115	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.37e-05	0.00114	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.14e-05	0.00108	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.04e-05	0.00106	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.95e-05	0.00103	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.82e-05	0.001	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.81e-05	0.000997	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.64e-05	0.000951	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.53e-05	0.000925	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.46e-05	0.000906	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	3.45e-05	0.000903	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.28e-05	0.000859	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.28e-05	0.000859	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	3.25e-05	0.000849	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.23e-05	0.000845	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.17e-05	0.000829	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.1e-05	0.000811	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3e-05	0.000786	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.95e-05	0.000772	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	2.93e-05	0.000766	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.93e-05	0.000766	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.92e-05	0.000764	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—ESR1—urinary bladder cancer	2.71e-05	0.000709	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.7e-05	0.000707	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.6e-05	0.000681	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.55e-05	0.000668	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.52e-05	0.000659	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.49e-05	0.000651	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—PPARG—urinary bladder cancer	2.47e-05	0.000647	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	2.38e-05	0.000622	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.33e-05	0.000611	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.33e-05	0.000611	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.26e-05	0.000592	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.12e-05	0.000555	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.99e-05	0.00052	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.88e-05	0.000492	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.8e-05	0.000471	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.57e-05	0.000411	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.55e-05	0.000406	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.46e-05	0.000382	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.44e-05	0.000377	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.44e-05	0.000377	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.44e-05	0.000376	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.44e-05	0.000376	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—MYC—urinary bladder cancer	1.41e-05	0.000369	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.39e-05	0.000365	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.38e-05	0.000361	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.36e-05	0.000355	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.27e-05	0.000333	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.16e-05	0.000303	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.03e-05	0.00027	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	9.93e-06	0.00026	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.67e-06	0.000253	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.99e-06	0.000235	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.88e-06	0.000232	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.88e-06	0.000232	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.51e-06	0.000223	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.35e-06	0.000219	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	8.13e-06	0.000213	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.85e-06	0.000205	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTEN—urinary bladder cancer	7.09e-06	0.000185	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—EP300—urinary bladder cancer	6.76e-06	0.000177	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.37e-06	0.000167	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.12e-06	0.00016	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.01e-06	0.000131	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.37e-06	0.000114	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.16e-06	0.000109	CbGpPWpGaD
